HCW Biologics
HCWB
12 hedge funds and large institutions have $1.5M invested in HCW Biologics in 2022 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 4 increasing their positions, 2 reducing their positions, and 1 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 2
20% more capital invested
Capital invested by funds: $1.25M → $1.5M (+$248K)
0% more funds holding
Funds holding: 12 → 12 (0)
0% more ownership
Funds ownership: 0.01% → 0.01% (+0%)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
+$181K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$20.1K |
| 3 |
Morgan Stanley
New York
|
+$6.88K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$6.88K |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$573 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$5K |
| 2 |
Two Sigma Investments
New York
|
-$3.44K |
| 3 |
BlackRock
New York
|
-$2.87K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
1
HighTower Advisors
Chicago,
Illinois
| $517K | – | – | – |
|
|
2
Geode Capital Management
Boston,
Massachusetts
| $300K | +$181K | +316 | +137% |
|
|
3
Vanguard Group
Malvern,
Pennsylvania
| $218K | +$20.1K | +35 | +10% |
|
|
BCM
4
Bridgeway Capital Management
Houston,
Texas
| $166K | – | – | – |
|
|
5
BlackRock
New York
| $96K | -$2.87K | -5 | -3% |
|
|
6
Two Sigma Investments
New York
| $87K | -$3.44K | -6 | -4% |
|
7
State Street
Boston,
Massachusetts
| $49K | – | – | – |
|
|
CAM
8
Cresset Asset Management
Chicago,
Illinois
| $40K | – | – | – |
|
|
TRCT
9
Tower Research Capital (TRC)
New York
| $15K | +$6.88K | +12 | +80% |
|
|
10
Morgan Stanley
New York
| $8K | +$6.88K | +12 | +600% |
|
|
FWM
11
Focused Wealth Management
Newburgh,
New York
| $2K | – | – | – |
|
|
12
UBS Group
Zurich,
Switzerland
| – | -$5K | -9 | Closed |
|
|
13
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | +$573 | +1 | New |
|
HCWB Hedge Fund Activity: Q3 2022 in Review
12 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in HCW Biologics (HCWB) for Q3 2022, worth a combined $1.5M — up 20% from $1.25M a quarter earlier.
Fund positioning in HCWB was balanced in Q3 2022: 1 fund opened new positions, 1 closed out, 4 added to existing stakes and 2 trimmed.
The largest buyer was Geode Capital Management, adding an estimated $181K. The largest seller was UBS Group, exiting entirely with an estimated $5K sold.
- 12 institutional investors held HCW Biologics (HCWB) as of Q3 2022, unchanged from Q2 2022.
- Funds reported $1.5M of HCW Biologics stock for Q3 2022, up 20% quarter-over-quarter.
- 1 fund opened new HCW Biologics positions in Q3 2022 and 1 closed out, a net change of 0 holders.
- The largest HCW Biologics buyer in Q3 2022 was Geode Capital Management, an estimated $181K added.
- The largest HCW Biologics seller in Q3 2022 was UBS Group, an estimated $5K sold.
Based on aggregated 13F filings for Q3 2022.